Shire Reports on Director/PDMR Share Dealings
Type of Security (1) |
Number of Shares/ADSs |
|
Dominic Blakemore |
Shares |
137 |
Olivier Bohuon |
Shares |
163 |
William Burns |
Shares |
156 |
Dr. Steven Gillis |
ADSs |
53 |
Dr. David Ginsburg |
ADSs |
49 |
David Kappler |
Shares |
144 |
Susan Kilsby |
ADSs |
155 |
Sara Mathew |
ADSs |
60 |
Anne Minto |
Shares |
158 |
(1) One ADS is equal to three Shares.
The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ respectively at ?44.567 per Share and \\$198.0411 per ADS.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.
In addition, for the purposes of the EU Transparency Directive, it is noted that the Company’s Home Member State is the United Kingdom.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
Комментарии